Topical microbicides to prevent HIV: Clinical drug development challenges

Annual Review of Pharmacology and Toxicology

Volumn 49, Issue , 2009, Pages 349-375

  Hendrix, Craig W ^a   Ying, Jun Cao ^a   Fuchs, Edward J ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adverse events; Antiretroviral drugs; Clinical trial simulation; Pharmacodynamics; Pharmacokinetics; Pre exposure prophylaxis

Indexed keywords

ACIDFORM; CARBOPOL 974P; CARRAGEENAN; CELLACEFATE; CELLULOSE SULFATE; DAPIVIRINE; INVISIBLE CONDOM; MARAVIROC; MICROBICIDE; MIV 150; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NONOXINOL 9; PRO 2000; RNA DIRECTED DNA POLYMERASE; SAVVY; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; VIVAGEL; TOPICAL ANTIINFECTIVE AGENT;

CLINICAL TRIAL; COMPARTMENT MODEL; DISEASE PREDISPOSITION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TISSUE LEVEL; HALF LIFE TIME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; LIME (FRUIT); PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; SEROCONVERSION; TOXICITY TESTING; ANIMAL; CLINICAL PHARMACOLOGY; METHODOLOGY; NOMENCLATURE; THEORETICAL MODEL;

ANIMALS; ANTI-INFECTIVE AGENTS, LOCAL; CLINICAL TRIALS AS TOPIC; HIV INFECTIONS; HUMANS; MODELS, THEORETICAL; PHARMACOLOGY, CLINICAL; TERMINOLOGY AS TOPIC;

EID: 65249168098     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.48.113006.094906     Document Type: Review

References (97)

1. Microbicide Pipeline. 2008. Silver Spring, MD: Alliance Microbicide Res.
2. Family Health Int. 2006. Phase 3 trial in Nigeria evaluating the effectiveness of SAVVY Gel in preventing HIV infection in women will close-Aug. 28.
3. Johansson E. 2008. Population council: Results of Phase III Carraguard trial. Special symposium. Presented at Microbicides 2008 Conference, New Delhi, India
4. van Damme L. 2008. The closing of CONRAD'S cellulose sulfate HIV prevention trial. Presented at Annu. Meet. HIV Prev. Trials Netw., Arlington, VA
5. Mesquita P,Wilson S, Cheshenko N, Keller M, Galen B, Herold B. 2008. Comprehensive pre-clinical assessment of microbicide safety using in vitro and murine models. Presented at 15th Conf. Retrovir. Opportunistic Infect., Boston, MA
6. Hamer DH. 2008. Cellulose sulfate increases HIV infection. Presented at Microbicides 2008 Conference, New Delhi, India
7. Fuchs EJ, Lee LA, Torbenson MS, Parsons TL, Bakshi RP, et al. 2007. Hyperosmolar sexual lubricant causes epithelial damage in the distal colon: Potential implication for HIV transmission. J. Infect. Dis. 195:703-10
8. van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, et al. 2002. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 360:971-77
9. Hillier SL, Moench T, Shattock R, Black R, Reichelderfer P, Veronese F. 2005. In vitro and in vivo: the story of nonoxynol 9. J. Acquir. Immune. Defic. Syndr. 39:1-8
10. Padian NS, van der Straten A, Ramjee G, Chipato T, de Bruyn G, et al. 2007. Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial. Lancet 370:251-61
11. Watson-Jones D,Weiss HA, Rusizoka M, Changalucha J, Baisley K, et al. 2008. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N. Engl. J. Med. 358:1560-71
12. Robertson M, Mehrotra D, Fitzgerald D, Duerr A, Casimiro D, et al. 2008. Efficacy results from the STEP Study (Merck V520 Protocol 023/HVTN 502):APhase II test-of-concept trial of the MRKAd5HIV-1 Gag/Pol/Nef Trivalent vaccine. Presented at 15th Conf. Retrovir. Opportunistic Infect., Boston, MA
13. Lagakos SW, Gable AR. 2008. Challenges to HIV prevention-seeking effective measures in the absence of a vaccine. N. Engl. J. Med. 358:1543-45
14. Sheiner LB. 1997. Learning versus confirming in clinical drug development. Clin. Pharmacol. Ther. 61:275-91
15. Moss AR, Osmond D, Bacchetti P, Chermann JC, Barre-Sinoussi F, Carlson J. 1987. Risk factors for AIDS and HIV seropositivity in homosexual men. Am. J. Epidemiol. 125:1035-47
16. Chmiel JS, Detels R, Kaslow RA, Van Raden M, Kingsley LA, Brookmeyer R. 1987. Factors associated with prevalent human immunodeficiency virus (HIV) infection in the Multicenter AIDS Cohort Study. Am. J. Epidemiol. 126:568-77
17. Coates RA, Calzavara LM, Read SE, Fanning MM, Shepherd FA, et al. 1988. Risk factors for HIV infection in male sexual contacts of men with AIDS or an AIDS-related condition. Am. J. Epidemiol. 128:729-39
18. Myer L, Denny L, de Souza M, Wright TC Jr, Kuhn L. 2006. Distinguishing the temporal association between women's intravaginal practices and risk of human immunodeficiency virus infection: a prospective study of South African women. Am. J. Epidemiol. 163:552-60
19. DeGruttola V, Seage GR 3rd, Mayer KH, Horsburgh CR Jr. 1989. Infectiousness of HIV between male homosexual partners. J. Clin. Epidemiol. 42:849-56
20. Mastro TD, de Vincenzi I. 1996. Probabilities of sexual HIV-1 transmission. AIDS 10(Suppl. A):S75-82
21. Wiley JA, Herschkorn SJ, Padian NS. 1989. Heterogeneity in the probability of HIV transmission per sexual contact: the case of male-to-female transmission in penile-vaginal intercourse. Stat. Med. 8:93-102
22. Moss GB, Clemetson D, D'Costa L, Plummer FA, Ndinya-Achola JO, et al. 1991. Association of cervical ectopy with heterosexual transmission of human immunodeficiency virus: results of a study of couples in Nairobi, Kenya. J. Infect Dis. 164:588-91
23. Myer L, Wright TC Jr, Denny L, Kuhn L. 2006. Nested case-control study of cervical mucosal lesions, ectopy, and incident HIV infection among women in Cape Town, South Africa. Sex. Transm. Dis. 33:683-87
24. Exner TM, Correale J, Carballo-Dieguez A, Salomon L, Morrow KM, et al. 2008. Women's anal sex practices: implications for formulation and promotion of a rectal microbicide. AIDS Educ. Prev. 20:148-59
25. Hillier SL, Joshi S, Cyrus-Cameron E, Hendrix CW, Justman J, et al. 2008. Safety and acceptability of daily and coitally dependent use of 1% tenofovir over six months of use. Presented at Microbicides 2008 Conference, New Delhi, India
26. Gorbach PM, Manhart LE, Stoner BP, Martin DH. 2006. Anal intercourse among young heterosexuals in three US STD clinics populations. Presented at XVI Int. AIDS Conf., Toronto, Can.
27. Shattock RJ, Moore JP. 2003. Inhibiting sexual transmission of HIV-1 infection. Nat. Rev. Microbiol. 1:25-34
28. Haase AT. 2005. Perils at mucosal front lines for HIV and SIV and their hosts. Nat. Rev. Immunol. 5:783-92
29. Phillips DM, Taylor CL, Zacharopoulos VR, Maguire RA. 2000. Nonoxynol-9 causes rapid exfoliation of sheets of rectal epithelium. Contraception 62:149-54
30. Phillips DM, Sudol KM, Taylor CL, Guichard L, Elsen R, Maguire RA. 2004. Lubricants containing N-9 may enhance rectal transmission of HIV and other STIs. Contraception 70:107-10
31. Miller CJ, Shattock RJ. 2003. Target cells in vaginal HIV transmission. Microbes Infect. 5:59-67
32. Borkow G, Barnard J, Nguyen TM, Belmonte A, Wainberg MA, Parniak MA. 1997. Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase. J. Virol. 71:3023-30
33. Wilkinson J, Cunningham AL. 2006. Mucosal transmission of HIV-1: first stop dendritic cells. Curr. Drug Targets 7:1563-69
34. Fernandez-Romero JA, Thorn M, Turville SG, Titchen K, Sudol K, et al. 2007. Carrageenan/MIV-150 (PC-815), a combination microbicide. Sex. Transm. Dis. 34:9-14
35. Cone RA, Hoen T, Wong X, Abusuwwa R, Anderson DJ, Moench TR. 2006. Vaginal microbicides: detecting toxicities in vivo that paradoxically increase pathogen transmission. BMC Infect. Dis. 6:90
36. Bangsberg D, Hecht F, Charlebois E, Chesney M, Moss AR. 2001. Comparing objectives measures of adherence to HIV antiretroviral therapy: Electronic medication monitors and unannounced pill counts. AIDS Behav. 5:275-81
37. Carballo-Diéguez A, Remien R, Dolezal C, Wagner G. 1999. Reliability of sexual behavior self-reports in male couples of discordant HIV-status. J. Sex. Res. 36:152-58
38. Grymonpre RE, Didur CD, Montgomery PR, Sitar DS. 1998. Pill count, self-report, and pharmacy claims data to measure medication adherence in the elderly. Ann. Pharmacother. 32:749-54
39. Lee JY, Greene PG, Douglas M, Grim C, Kirk KA, et al. 1996. Appointment attendance, pill counts, and achievement of goal blood pressure in the African American Study of Kidney Disease and Hypertension Pilot Study. Control Clin. Trials 17:S34-39
40. Villarroel MA,Turner CF, Rogers SM, Roman AM, Cooley PC, et al. 2008.T-ACASI reduces bias in STD measurements: the National STD and Behavior Measurement Experiment. Sex. Transm. Dis. 35:499-506
41. Wallace A, Thorn M, Maguire RA, Sudol KM, Phillips DM. 2004. Assay for establishing whether microbicide applicators have been exposed to the vagina. Sex. Transm. Dis. 31:465-68
42. Hogarty K, Kasowitz A, Herold BC, Keller MJ. 2007. Assessment of adherence to product dosing in a pilot microbicide study. Sex. Transm. Dis. 34:1000-3
43. Hillier SL. 2008. Evaluation of the applicator dye test for HTI applicators. Presented at Annu. Meet. Microbicide Trial Netw., Arlington, VA
44. Simoni JM, Kurth AE, Pearson CR, Pantalone DW, Merrill JO, Frick PA. 2006. Self-report measures of antiretroviral therapy adherence: A review with recommendations for HIV research and clinical management. AIDS Behav. 10:227-45
45. Bangsberg DR, Hecht FM, Charlebois ED, Zolopa AR, Holodniy M, et al. 2000. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 14:357-66
46. Barditch-Crovo P, Deeks SG, Collier A, Safrin S, Coakley DF, et al. 2001. Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob. Agents Chemother. 45:2733-39
47. Mayer KH, Maslankowski LA, Gai F, El-Sadr WM, Justman J, et al. 2006. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS 20:543-51
48. Kashuba A. 2008. Genital compartmentalization of orally and topically administered antiretrovirals. Presented at 15th Conf. Retrovir. Opportunistic Infect., Boston, MA
49. Schwartz J, Kashuba A, Rezk N, Nasution M, Choi SO, et al. 2008. Preliminary results from a pharmacokinetic study of the candidate vaginal microbicide agent 1% tenofovir gel. Presented at Microbicides 2008 Conference, New Delhi, India
50. Dumond JB, Yeh RF, Patterson KB, Corbett AH, Jung BH, et al. 2007. Antiretroviral drug exposure in the female genital tract: implications for oral pre- and postexposure prophylaxis. AIDS 21:1899-907
51. Romano J, Variano B, Coplan P, van Roey J, Douville K, et al. 2007. Sustained delivery of microbicide dapivirine using intra-vaginal rings: An independent clinical assessment of Safety & Drug Delivery in Women. Presented at 14th Conf. Retrovir. Opportunistic Infect., Los Angeles, CA
52. Hawkins T, Veikley W, St. Claire RL 3rd, Guyer B, Clark N, Kearney BP. 2005. Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J. Acquir. Immune Defic. Syndr. 39:406-11
53. Robbins BL, Srinivas RV, Kim C, Bischofberger N, Fridland A. 1998. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2- phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA. Antimicrob. Agents Chemother. 42:612-17
54. Anderson PL, Zheng JH, King T, Bushman LR, Predhomme J, et al. 2007. Concentrations of zidovudine- and lamivudine-triphosphate according to cell type in HIV-seronegative adults. AIDS 21:1849-54
55. Vourvahis M, Tappouni HL, Patterson KB, Chen YC, Rezk NL, et al. 2008. The pharmacokinetics and viral activity of tenofovir in the male genital tract. J. Acquir. Immune Defic. Syndr. 47:329-33
56. Kiser JJ, Aquilante CL, Anderson PL, King TM, Carten ML, Fletcher CV. 2008. Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients. J. Acquir. Immune Defic. Syndr. 47:298-303
57. Mauck CK, Katz D, Sandefer EP, Nasution MD, Henderson M, et al. 2008. Vaginal distribution of Replens and K-Y Jelly using three imaging techniques. Contraception 77:195-204
58. Barnhart KT, Stolpen A, Pretorius ES, Malamud D. 2001. Distribution of a spermicide containing Nonoxynol-9 in the vaginal canal and the upper female reproductive tract. Hum. Reprod. 16:1151-54
59. Barnhart KT, Pretorius ES, Timbers K, Shera D, Shabbout M, Malamud D. 2004. In vivo distribution of a vaginal gel: MRI evaluation of the effects of gel volume, time and simulated intercourse. Contraception 70:498-505
60. Barnhart KT, Pretorius ES, Timbers K, Shera D, Shabbout M, Malamud D. 2005. Distribution of a 3.5-ml (1.0%) C31G vaginal gel using magnetic resonance imaging. Contraception 71:357-61
61. Barnhart KT, Pretorius ES, Shaunik A, Timbers K, Nasution M, Mauck C. 2005. Vaginal distribution of two volumes of the novel microbicide gel cellulose sulfate (2.5 and 3.5 mL). Contraception 72:65-70
62. Witter F, Barditch-Crovo P, Rocco L, Trapnell CB. 1999. Duration of vaginal retention and potential duration of antiviral activity for five nonoxynol-9 containing intravaginal contraceptives. Int. J. Gynecol. Obstet. 65:165-70
63. Henderson MH, Peters JJ, Walmer DK, Couchman GM, Katz DF. 2005. Optical instrument for measurement of vaginal coating thickness by drug delivery formulations. Rev. Sci. Instr. 76:1-7
64. Henderson MH, Couchman GM, Walmer DK, Peters JJ, Owen DH, et al. 2007. Optical imaging and analysis of human vaginal coating by drug delivery gels. Contraception 75:142-51
65. Braun KE, Boyer JD, Henderson MH, Katz DF,Wax A. 2006. Label-free measurement of microbicidal gel thickness using low-coherence interferometry. J. Biomed. Opt. 11:020504
66. Geonnotti AR, Katz DF. 2006. Dynamics of HIV neutralization by a microbicide formulation layer: biophysical fundamentals and transport theory. Biophys. J. 91:2121-30
67. Jay M, Digenis GA, Foster TS, Antonow DR. 1986. Retrograde spreading of hydrocortisone enema in inflammatory bowel disease. Dig. Dis. Sci. 31:139-44
68. Hendrix CW, Fuchs EJ, Macura KJ, Lee LA, Parsons TL, et al. 2008. Quantitative imaging and sigmoidoscopy to assess distribution of rectal microbicide surrogates. Clin. Pharmacol. Ther. 83:97-105
69. Hastie T, Stuetzle W. 1989. Principal curves. J. Am. Stat. Assoc. 84:502-16
70. Cao YJ, Caffo BS, Fuchs EJ, Lee LA, Parsons TL, et al. 2008. Three-dimensional Spect/Ct curve fitting algorithm with local density distribution compared to direct methods for quantitation of the distribution of rectallyapplied HIV-sized particles. Presented at Annu. Meet. Am. Soc. Clin. Pharmacol. Ther., Orlando, FL
71. Barnhart KT, Timbers K, Pretorius ES, Lin K, Shaunik A. 2005. In vivo assessment of Nuva Ring placement. Contraception 72:196-99
72. Carballo-Diéguez A, Bauermeister JA, Ventuneac A, Dolezal C, Balan I, Remien RH. 2007. The use of rectal douches among HIV-uninfected and infected men who have unprotected receptive anal intercourse: implications for rectal microbicides. AIDS Behav. In press
73. Hylton J, Fuchs E, Hendrix CW. 2004. An assessment of sexual practices affecting the feasibility of microbicide development among MSM. Presented at Microbicides 2004, London (Abstr. 2667)
74. Hylton J, Fuchs EJ, Hendrix CW. 2006. Lubricant and enema use among MSM: factors affecting the development of a rectal microbicide for clinical trials. Presented at XVI Int. AIDS Conf., Toronto, Can.
75. Nimmagadda S, Fuchs EJ, Cao YJ, Louissaint N, Bakshi RP, et al. 2007. Autologous lymphocytes and HIV-sized particles in autologous seminal plasma penetrate colonic tissue following simulated receptive anal intercourse in healthy men. 4th IAS Conf. HIV Pathog., Treat., Prev., Sydney, Aust.
76. Herold B. 2008. Safety of tenofovir gel in a comprehensive murine model. Presented at Microbicides 2008 Conference, New Delhi, India
77. Dezzutti CS, James VN, Ramos A, Sullivan ST, Siddig A, et al. 2004. In vitro comparison of topical microbicides for prevention of human immunodeficiency virus type 1 transmission. Antimicrob. Agents Chemother. 48:3834-44
78. Abner SR, Guenthner PC, Guarner J, Hancock KA, Cummins JE Jr, et al. 2005.Ahuman colorectal explant culture to evaluate topical microbicides for the prevention of HIV infection. J. Infect. Dis. 192:1545-56
79. Lackman-Smith C, Osterling C, Luckenbaugh K, Mankowski M, Snyder B, et al. 2008. Development of a comprehensive human immunodeficiency virus type 1 screening algorithm for discovery and preclinical testing of topical microbicides. Antimicrob. Agents Chemother. 52:1768-81
80. McGowan I, Elliott J, Cortina G,Tanner K, Siboliban C, et al. 2007. Characterization of baseline intestinal mucosal indices of injury and inflammation in men for use in rectal microbicide trials (HIV Prevention Trials Network-056). J. Acquir. Immune. Defic. Syndr. 46:417-25
81. Tabet SR, Surawicz C, Horton S, Paradise M, Coletti AS, et al. 1999. Safety and toxicity of nonoxynol-9 gel as a rectal microbicide. Sex. Transm. Dis. 26:564-71
82. Feil W, Lacy ER,Wong YM, Burger D,Wenzl E, et al. 1989. Rapid epithelial restitution of human and rabbit colonic mucosa. Gastroenterology 97:685-701
83. Vincent KL, Bell BA, Rosenthal SL, Stanberry LR, Bourne N, et al. 2008. Application of optical coherence tomography for monitoring changes in cervicovaginal epithelial morphology in macaques: potential for assessment of microbicide safety. Sex. Transm. Dis. 35:269-75
84. Bjarnason I, Peters TJ, Veall N. 1984. 51Cr-EDTA test for intestinal permeability. Lancet 2:523
85. Fuchs EJ, Grohskopf LA, Lee LA, Hendrix CW. 2008. Detecting rectal epithelial disruption using radioisotopes: A simple test to identify potential HIV microbicide toxicity. Presented at Microbicides 2008 Conference, New Delhi, India
86. Cai C, Sawant S, Qi Z, McCormack S, Weber JN, et al. 2008. Unacceptable side effects of a hyperosmolar vaginal microbicide in a phase 1 trial. Presented at Microbicides 2008 Conference, New Delhi, India
87. Muranishi S. 1990. Absorption enhancers. Crit. Rev. Ther. Drug Carr. Syst. 7:1-33
88. Aungst BJ. 2000. Intestinal permeation enhancers. J. Pharm. Sci. 89:429-42
89. Kameda H, Abei T, Nasrallah S, Iber FL. 1968. Functional and histological injury to intestinal mucosa produced by hypertonicity. Am. J. Physiol. 214:1090-95
90. Rubsamen K, Hornicke H. 1982. Influence of osmolality, short chain fatty acids and deoxycholic acid on mucus secretion in the rat colon. Pflügers Arch. 395:306-11
91. Billich CO, Levitan R. 1969. Effects of sodium concentration and osmolality on water and electrolyte absorption form the intact human colon. J. Clin. Invest. 48:1336-47
92. Meisel JL, Bergman D, Graney D, Saunders DR, Rubin CE. 1977. Human rectal mucosa: proctoscopic and morphological changes caused by laxatives. Gastroenterology 72:1274-79
93. Schmelzer M, Schiller LR, Meyer R, Rugari SM, Case P. 2004. Safety and effectiveness of large-volume enema solutions. Appl. Nurs. Res. 17:265-74
94. Dezzutti CS. 2008. Impact of semen on HIV-1 infection and in vitro antiviral activity of topical microbicides. Presented at Microbicides 2008 Conference, New Delhi, India
95. Johnson EJ. 2008. The effect of semen on colorectal explant morphology, viability, and HIV-1 infection. Presented at Microbicides 2008 Conference, New Delhi, India
96. Mendizabal MV, Naftalin RJ. 1992. Effects of spermine on water absorption, polyethylene glycol 4000 permeability and collagenase activity in rat descending colon in vivo. Clin. Sci. 83:417-23
97. Alexander NJ, Tarter TH, Fulgham DL, Ducsay CA, Novy MJ. 1987. Rectal infusion of semen results in transient elevation of blood prostaglandins. Am. J. Reprod. Immunol. Microbiol. 15:47-51